Targeting FoxP3 poses significant challenges. FoxP3 is critical for immune homeostasis, and its inhibition could lead to severe autoimmune reactions. Additionally, the heterogeneity of Tregs and their plasticity in the tumor microenvironment complicate therapeutic approaches. Moreover, identifying specific markers that exclusively target tumor-promoting Tregs without affecting normal Tregs remains a critical hurdle.
